Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05765084 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

Study acronym: Immuno-MESODEC
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Oct 2026 to Oct 2027v6
  2. Re-verified, no change to tracked fieldsv5
  3. Eligibility criteria expanded, about 4 wordsv4
  4. Start date changed from estimate of Mar 2023 to Feb 24, 2023v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 3 of 3 sites
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In this multicenter phase I/II trial, the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab and dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen WT1 will be integrated into platinum/pemetrexed-based first-line chemotherapy for the treatment of epitheloid malignant pleural mesothelioma (MPM). The general objective is to provide the first-in-human experimental demonstration that the combination of platinum/pemetrexed-based chemotherapy with atezolizumab and WT1/DC vaccination is feasible and safe, has clinical activity and enables the induction of mesothelioma-specific immune responses in patients with MPM.
Trial Details
NCT Number NCT05765084
Lead Sponsor University Hospital, Antwerp
Collaborators: Algemeen Ziekenhuis Maria Middelares, Vitaz, Kom Op Tegen Kanker, Roche Pharma AG
Conditions
(from sponsor)		 Malignant Pleural Mesothelioma
Related terms Mesothelioma, Malignant, Wilms Tumor
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov